The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Komarov S.D.
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Vdovin A.S.
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Vinnikova M.A.
Sechenov First Moscow State Medical University (Sechenov University);
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Severtsev V.V.
Sechenov First Moscow State Medical University (Sechenov University);
Scientific and Practical Toxicology Center Federal Medical and Biological Agency of Russia
Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12): 57‑62
Views: 5793
Downloaded: 215
To cite this article:
Komarov SD, Vdovin AS, Vinnikova MA, Severtsev VV, Komarov SD, Vdovin AS. Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study. S.S. Korsakov Journal of Neurology and Psychiatry.
2021;121(12):57‑62. (In Russ.)
https://doi.org/10.17116/jnevro202112112157
Assess the efficacy and safety of fluvoxamine, sertraline, citalopram, paroxetine, fluoxetine.
The study included 175 patients with alcohol dependence and depressive disorders. 161 had a diagnosis Alcohol Dependence Syndrome (ADS); 14 patients had a «dual diagnosis». All patients were randomized into 5 groups according to the drugs received. To assess the therapeutic efficacy of drugs, the following scales were used: visual analogue scale (VAS), Montgomery-Asberg Depression Rating Scale (MADRS), Hospital Anxiety and Depression Scale (HADS). The safety of drugs was assessed by the incidence of adverse events (AEs) or serious adverse events (SAEs).
The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy. A significant decrease in the level of anxiety when taking fluvoxamine and citalopram occurs by the 7th day, when taking sertraline and paroxetine — by the 14th day, and when taking fluoxetine — by the 30th day. The presence of an anticraving effect in SSRIs is confirmed by the obtained strong and average correlation coefficients between affective disorders and craving for alcohol. The correlation analysis allowed drawing the conclusions about the close connection of presenting features of the affective disorders (depression and anxiety) and craving. The anticraving effect is more expressive in fluvoxamine, sertraline, citalopram and paroxetine. The most common adverse reactions (increased insomnia and anxiety) are observed in: fluoxetine, citalopram, sertraline, paroxetine. Fluvoxamine has the most favorable safety profile.
SSRIs can be effectively used for the treatment of depressive disorders in alcohol dependence.
Keywords:
Authors:
Komarov S.D.
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Vdovin A.S.
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Vinnikova M.A.
Sechenov First Moscow State Medical University (Sechenov University);
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Severtsev V.V.
Sechenov First Moscow State Medical University (Sechenov University);
Scientific and Practical Toxicology Center Federal Medical and Biological Agency of Russia
Received:
17.11.2021
Accepted:
06.12.2021
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.